Silence Therapeutics
advancing an siRNA pipeline in rare blood and cardiometabolic disease on its mRNAi GOLD platform, with promising 2026 clinical results reported in its June 2026 corporate presentation.
- Country
- United Kingdom
- Ticker
- SLN
siRNA rare-blood pipeline
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Nucleic acid therapeutics (oligonucleotides) | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.